Vivozon Pharmaceutical Co., Ltd.
Financials
Valuation Metrics
Vivozon Pharmaceutical Co., Ltd.'s Market Cap is ₩1518B. At end of 2025 it was ₩2336B. Ranked #984 of 2,436 in KR market (top 40%), #484 of 1,649 on KOSDAQ (top 29%), #116 of 234 in Pharmaceuticals, Biotechnology & Life Sciences (top 50%) by Market Cap.
Investment Metrics(as of 2026-08-04)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | 151.80B KRW | KR#984/2,436 Sec#116/234 |
| Revenue | 54.86B KRW | KR#1,730/2,436 Sec#118/234 |
| Net Income | -34.21B KRW | KR—/2,436 Sec—/234 |
| Total Assets | 170.75B KRW | KR#1,378/2,436 Sec#108/234 |
| Net Assets | 97.74B KRW | KR#1,417/2,436 Sec#117/234 |
| Employees | 394 | KR#617/2,436 Sec#53/234 |
| Value | ||
| P/B | 1.55x | KR#1,809/2,436 Sec#131/234 |
| P/S | 2.77x | KR#1,981/2,436 Sec#121/234 |
| FCF Yield | -5.46% | KR—/2,436 Sec—/234 |
| Profitability | ||
| ROE | -35.00% | KR#2,205/2,436 Sec#182/234 |
| ROA | -20.04% | KR#2,232/2,436 Sec#177/234 |
| Op. Margin | -35.87% | KR#2,202/2,436 Sec#158/234 |
| Revenue Growth | -24.10% | KR#2,107/2,436 Sec#191/234 |
| Financial Health | ||
| Debt Ratio | 174.70% | KR#1,481/2,436 Sec#170/234 |
| Total Debt | 35.08B KRW | KR#1,125/2,436 Sec#86/234 |
| FCF | -8.28B KRW | KR#1,656/2,436 Sec#136/234 |
| Cash | 14.19B KRW | KR#1,460/2,436 Sec#109/234 |
| Current Ratio | 0.71x | KR#2,124/2,436 Sec#202/234 |
| Performance | ||
| 1Y Return | -63.00% | KR#2,282/2,436 Sec#216/234 |
| 1M Return | -0.40% | KR#921/2,436 Sec#83/234 |
| From 52W High | -68.94% | KR#2,092/2,436 Sec#185/234 |
| 1Y MDD | -72.18% | KR#2,038/2,436 Sec#180/234 |
| Trading | ||
| Volume | 141,394 shares | KR#750/2,436 Sec#72/234 |
| Foreign Own. | 1.65% | KR#1,117/2,436 Sec#109/234 |
| Per Share | ||
| EPS | -636 KRW | KR—/2,436 Sec—/234 |
| BPS | 1,624 KRW | KR#2,128/2,436 Sec#185/234 |
Company Info
VIVAZON Pharm, established in 2002 and listed on KOSDAQ in 2005, is a finished pharmaceutical product manufacturing and sales company. It possesses over 190 items, including cardiovascular drugs, dermatological external preparations, and antipyretic analgesics and anti-inflammatory drugs, engaging in ETC, OTC, CMO, OEM businesses, and overseas exports. The company's pharmaceutical research institute focuses on developing generics, combination drugs, formulation changes, and differentiated products using controlled-release technology. VIVAZON Pharm is headquartered in Hwaseong-si, Gyeonggi-do.